Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This prospective phase II study is determined to explore the efficacy and safety of
radiotherapy and bevacizumab maintenance therapy for oligometastatic lung adenocarcinoma with
negative driver genes